

Interested Parties should contact:
Keith Ryan kryan@geneousbiomedical.com
617 444 8780



INVESTMENT OPPORTUNITY – ALZHEIMERS DISEASE

A differentiated investment into the future \$14 B Alzheimer's drug market

Alzheimer's disease market:

- 5 million persons currently with Alzheimer's disease in the US
- Persons that sustain concussive head injuries are 2 to 4 times higher risk for Alzheimer's
- 35 million persons currently with Alzheimer's disease and major market countries
- \$6 Billion current annual sales of drugs that only treat symptoms of Alzheimer's disease
- \$14 Billion annual drug sales by 2020, if there were treatments that prevented the disease
- \$172 Billion annual 2010 US expenditure cure for Alzheimer's patients
- \$1.1 Trillion predicted annual 2050 US expenditure to care for Alzheimer's patients

Our client partner, **AZTherapies** is in the unique position of developing a therapeutic drug for Alzheimer's disease which has **already been approved by the FDA** for a different disease. The repurposing of an already approved drug fast tracks clinical development and streamlines the path to market. The drug is easily administered by inhalation for daily dosing. This drug has a remarkably clean safety and tolerability record, even for long term use - a key point when considering long-term dosing to prevent Alzheimer's disease and dementia.

AZTherapies is executing on mid-stage (phase 2) trials to treat persons who are just beginning to show signs of memory and functional impairment. Their goal is to determine what treatment does will be best for preventing further cognitive and functional decline.

Targeted of M&A or IPO by end of 2015:

They are currently recruiting \$7 million to support phase 2 trials of this previously approved drug, which will start in Q1 2013. The first data from this trial will be available in early 2014. They are planning to raise an additional \$25 million to achieve key corporate goals for company valuation inflection with \$396 million estimated net present value.

Please contact us for more detailed information.

617 444 8780

kryan@geneousbiomedical.com